ACID ZOLEDRONIC FRESENIUS KABI 4mg / 5ml perfusive solution concentrate medication leaflet

M05BA08 zoledronic acid • Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates

Zoledronic acid is a bisphosphonate used to treat osteoporosis, Paget's disease of the bone, and to prevent skeletal complications in patients with bone metastases. It is also used to treat hypercalcemia associated with cancer.

It works by inhibiting osteoclast-mediated bone resorption, leading to increased bone density and reduced risk of fractures. It is administered intravenously, usually once a year for osteoporosis or more frequently for other indications.

Common side effects include fever, muscle pain, flu-like symptoms, and injection site reactions. In rare cases, it may cause osteonecrosis of the jaw or kidney impairment.

Patients receiving zoledronic acid treatment should be well-hydrated and monitored for kidney function, especially if they have other conditions that may affect the kidneys.

General data about ACID ZOLEDRONIC FRESENIUS KABI 4mg / 5ml

Substance: zoledronic acid

Date of last drug list: 01-06-2025

Commercial code: W59090002

Concentration: 4mg / 5ml

Pharmaceutical form: perfusive solution concentrate

Quantity: 4

Product type: generic

Price: 696.58 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: FRESENIUS KABI AUSTRIA GMBH - AUSTRIA

Holder: FRESENIUS KABI ROMANIA S.R.L. - ROMANIA

Number: 11263/2018/02

Shelf life: 30 months-after packing for marketing; dupa dilutie-it is used immediately

Concentrations available for zoledronic acid

4mg, 4mg/100ml, 4mg/5ml, 5mg, 5mg/100ml

Compensation lists for ACID ZOLEDRONIC FRESENIUS KABI 4mg / 5ml FRESENIUS

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

696.58 RON

533.71 RON

162.87 RON